Forbion collected €2.3 billion across two new venture funds, described as its largest-ever fundraising haul. The investor said the capital will support roughly 30 companies, positioning the new vehicles for life-sciences investments as European VC fundraising remains under pressure compared with the U.S. and China. The fundraising is framed as a response to shifting deal-making conditions, with Forbion bucking the slowdown by securing substantial committed capital. For founders and portfolio companies, large renewed fund size can translate into more follow-on capacity and longer runway for clinical programs that require staging milestones before major liquidity events.